Rgenta Therapeutics, Inc.
Cambridge, Massachusetts, United States · Biotechnology, Health Care, Other
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 33
- Industries
- Biotechnology, Health Care, Other
- Status
- Private
- Website
- rgentatx.com
- Company page
Recent activity at Rgenta Therapeutics, Inc.
- : Rgenta Therapeutics (date of first sale on the SEC Form D)
- : Rgenta Therapeutics Raises $52M In Series A Financing
- : Rgenta Therapeutics, Inc.
- : Rgenta Therapeutics, Inc.
- : Rgenta Therapeutics, Inc.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Rgenta Therapeutics, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2026 | Venture | $41.9M |
| Nov 2022 | Series A | $52.0M |
| Feb 2022 | Venture | $8.9M |
| Feb 2020 | Venture | $6.0M |
Leadership
- Samuel, Senior Director
- Hualin Xi, Executive Officer, Director
- Zhiping Weng, Director
- Fei Shen, Director
- Sun Linghao, Director
- Judith Li, Director
- Debasish Roychowdhury, Director
- Hongbo Lu, Director
- Martin Heidecker, Director
Verified email and direct lines for Rgenta Therapeutics, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Rgenta Therapeutics, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Rgenta Therapeutics, Inc. in the news
- Rgenta Therapeutics Raises $52M in Series A Financing - PR Newswire (Nov 29, 2022)
- Rgenta Therapeutics Enters into a Collaboration with Lundbeck - PR Newswire (Aug 04, 2021)
- Rgenta Therapeutics Announces First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC) - PR Newswire (Oct 08, 2024)
Companies similar to Rgenta Therapeutics, Inc.
- Premier Partners · Biotechnology, Health Care, Venture Capital
- Nucleus Genomics · Biotechnology, Health Care, Other
- RADNOSTIX · Biotechnology, Health Care, Other
- Ignitedata (Delaware) · Biotechnology, Health Care, Other
- Angelini Ventures · Biotechnology, Health Care, Venture Capital
About Rgenta Therapeutics, Inc.: questions and answers
What does Rgenta Therapeutics, Inc. do?
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique
Where is Rgenta Therapeutics, Inc. headquartered?
Rgenta Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, United States.
How many employees does Rgenta Therapeutics, Inc. have?
Rgenta Therapeutics, Inc. has about 33 employees.
Has Rgenta Therapeutics, Inc. raised funding?
Yes. Fundz has recorded 4 funding events for Rgenta Therapeutics, Inc.. The most recent, $41.9M, was in Oct 2026.
What is the latest news on Rgenta Therapeutics, Inc.?
On Oct 19, 2026, Rgenta Therapeutics
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy